Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsDrug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.
Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.
1.
Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.
2.
novel technique for early myelodysplastic syndrome relapse detection in blood cancer patients.
3.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
4.
New opportunities for screening and treatment have been created by the identification of the genetic drivers of esophageal cancer.
5.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
1.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
2.
Nipple-Sparing Mastectomy: Oncologic Safety and Patient Selection Review
3.
Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections
4.
Understanding Vaso Occlusive Crisis: Symptoms, Causes, and Management Strategies
5.
Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Navigating the Complexities of Ph Negative ALL - Part XI
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge